FDA weighs a new kind of flu shot based on technology RFK Jr. has questioned

FDA Considers Approval of Moderna’s mRNA Influenza Vaccine Amid Regulatory Uncertainty

Ecorescuezone.com – For the latest stories on the science of healthy living, subscribe to NPR’s Health newsletter.

Health Secretary Robert F. Kennedy Jr. has maintained skepticism regarding mRNA vaccine technology for an extended period. Now, the Food and Drug Administration faces a critical decision about whether to authorize an innovative influenza vaccine developed using mRNA methodology.

Initial Rejection Creates Industry Shockwaves

The outcome of this regulatory review carries substantial weight for mRNA research advancement. In February, Moderna president Stephen Hoge visited one of the company’s manufacturing facilities when Charbel Haber, the head of regulatory affairs, approached him with evident concern.

“Charbel came up to me and just had a very nervous look on his face,” Hoge recalled. “And when your head of regulatory comes up and has a concerned look on … [his] face, you take it seriously.”

Moderna had recently received correspondence from the FDA. Hoge immediately joined Haber and gathered several colleagues in a nearby conference room to examine the situation.

“That’s where you pop it up on a screen and it hits you, you know, right in the face,” Hoge explained.

The FDA announced it would not proceed with reviewing Moderna’s application for its mRNA influenza vaccine, which amounted to an effective rejection. This decision surprised company leadership.

“We had talked to the FDA at every step along the way, including prior to filing,” Hoge noted. “And they had said, you can go forward and submit and we will conduct a review.”

Moderna publicly disclosed the situation, generating significant attention throughout the pharmaceutical sector. Critics expressed frustration over the FDA’s apparent reversal of position.

Regulatory Reconsideration and Market Implications

Within approximately one week, the agency reconsidered its stance and agreed to review the vaccine after Moderna committed to conducting an additional confirmatory study should the product reach commercial availability. By June, an advisory panel to the FDA recommended approval of the vaccine.

The agency faces a Wednesday deadline for its final determination. Should the FDA grant approval, Moderna’s vaccine would become the inaugural mRNA-based influenza shot available to consumers. However, the February reversal has already produced a cooling effect on market sentiment.

Rena Conti, a health economist at Boston University, emphasized that industry stakeholders and investors are monitoring developments closely because the United States represents their primary revenue source. These entities rely on the FDA maintaining consistency and fairness in its evaluations.

“They don’t want to spend money if they don’t think there’s going to be a way to actually make money on the other end,” Conti observed.

Additionally, the Department of Health and Human Services eliminated approximately $500 million in mRNA vaccine research funding during the previous summer.

Regarding the administration’s approach to experimental mRNA vaccines, an HHS spokesperson issued the following statement: “Under Secretary Kennedy’s leadership, HHS is advancing President Trump’s commitment to strengthen public health through gold-standard science, and FDA will continue applying rigorous, evidence-based standards to every product it reviews while supporting innovation that meets those standards.”

Hoge indicated that Moderna is postponing certain planned mRNA research initiatives until the regulatory landscape becomes clearer.

Impact on Smaller Biotechnology Companies

Jeff Coller, a professor at Johns Hopkins University who has examined mRNA technology for many years, noted that Moderna dominates the mRNA sector while most competitors are small biotechs employing merely twenty to thirty people.

“When you see the FDA rejecting a product that comes from Moderna, why is it that my little company would be able to push through?” Coller questioned.

Coller explained that the FDA’s actions, combined with HHS funding reductions, unsettled venture capital firms supporting numerous smaller biotechs developing mRNA therapies for conditions spanning Lyme disease to rare cancers.

This situation affects patients like Janusz Racz, a sixty-nine-year-old retired computer scientist residing in London. Two years ago, physicians discovered an inoperable Stage 3 lung cancer in Racz, catching him by surprise.

A dedicated runner and sailor with no prior symptoms, Racz found his tumor measured approximately the size of a golf ball. Without intervention, doctors predicted he would survive only a few months.

Racz enrolled in a clinical trial in London, becoming the first individual in the United Kingdom to receive an mRNA vaccine developed by BioNTech, which partnered with Pfizer on the initial COVID-19 vaccine.

“I decided just to participate because I saw that was a big chance,” Racz stated. “And also, as a scientist … I wanted to participate in such a program to give other patients a hope.”

Following a year of regular vaccinations, Racz’s cancer has disappeared. He is now planning for the future while the study continues for other participants.